Tyzavan Patent Expiration

Tyzavan is a drug owned by Hikma Pharmaceuticals Usa Inc. It is protected by 6 US drug patents filed from 2020 to 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 06, 2035. Details of Tyzavan's patents and their expiration are given in the table below.

Filter patents by

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12161690 Glycopeptide compositions
Nov, 2035

(10 years from now)

Active
US10039804 Glycopeptide compositions
Nov, 2035

(10 years from now)

Active
US10849956 Glycopeptide compositions
Nov, 2035

(10 years from now)

Active
US10188697 Glycopeptide compositions
Nov, 2035

(10 years from now)

Active
US11628200 Glycopeptide compositions
Nov, 2035

(10 years from now)

Active
US11517609 Glycopeptide compositions
Nov, 2035

(10 years from now)

Active

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Tyzavan's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Tyzavan's generic, the next section provides detailed information on ongoing and past EP oppositions related to Tyzavan patents.

Tyzavan's Oppositions Filed in EPO

Tyzavan has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 01, 2020, by Df-Mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte Parg Mbb. This opposition was filed on patent number EP15791287A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP15791287A Oct, 2020 df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte ParG mbB Revoked


US patents provide insights into the exclusivity only within the United States, but Tyzavan is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Tyzavan's family patents as well as insights into ongoing legal events on those patents.

Tyzavan's Family Patents

Tyzavan has patent protection in a total of 27 countries. It's US patent count contributes only to 20.4% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Tyzavan.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Tyzavan's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 06, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Tyzavan Generic API suppliers:

Vancomycin Hydrochloride is the generic name for the brand Tyzavan. 30 different companies have already filed for the generic of Tyzavan, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Tyzavan's generic

Alternative Brands for Tyzavan

There are several other brand drugs in the same treatment category and using the same active ingredient (Vancomycin Hydrochloride) as Tyzavan. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Abbvie
Teflaro Used for treating bacterial infections.
Baxter Hlthcare Corp
Zosyn In Plastic Container used for treating bacterial infections.
Cubist Pharms Llc
Cubicin Used for treating bacterial infections, including skin infections and bloodstream infections.
Sivextro Used for treating acute bacterial skin and skin structure infections caused by susceptible bacteria.
Cumberland
Vibativ Used for treating bacterial infections, including staphylococcal infections.
Hikma
Vancomycin Used for treating bacterial infections.
Lg Chem Ltd
Factive used for treating various bacterial infections.
Pfizer
Trovan Used for treating bacterial infections.
Trovan Preservative Free Used for treating bacterial infections.
Pf Prism Cv
Zmax used for treating bacterial infections.
Tygacil Used for treating bacterial infections.
Rempex
Minocin used for treating bacterial infections.
Shionogi Inc
Doribax Used for treating bacterial infections.
Wyeth Pharms
Zosyn Used for treating bacterial infections.

Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Vancomycin Hydrochloride. Given below is the list of those drugs and companies owning them.

Drug Owner Drug Name
Azurity
Firvanq Kit


Apart from brand drugs containing the same ingredient, some generics have also been filed for Vancomycin Hydrochloride, Tyzavan's active ingredient. Check the complete list of approved generic manufacturers for Tyzavan





About Tyzavan

Tyzavan is a drug owned by Hikma Pharmaceuticals Usa Inc. Tyzavan uses Vancomycin Hydrochloride as an active ingredient. Tyzavan was launched by Hikma in 2019.

Approval Date:

Tyzavan was approved by FDA for market use on 15 February, 2019.

Active Ingredient:

Tyzavan uses Vancomycin Hydrochloride as the active ingredient. Check out other Drugs and Companies using Vancomycin Hydrochloride ingredient

Dosage:

Tyzavan is available in solution form for intravenous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML) SOLUTION Prescription INTRAVENOUS
EQ 1.75GM BASE/350ML (EQ 5MG BASE/ML) SOLUTION Prescription INTRAVENOUS
EQ 500MG BASE/100ML (EQ 5MG BASE/ML) SOLUTION Prescription INTRAVENOUS
EQ 1GM BASE/200ML (EQ 5MG BASE/ML) SOLUTION Prescription INTRAVENOUS
EQ 2GM BASE/400ML (EQ 5MG BASE/ML) SOLUTION Prescription INTRAVENOUS
EQ 750MG BASE/150ML (EQ 5MG BASE/ML) SOLUTION Prescription INTRAVENOUS
EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML) SOLUTION Prescription INTRAVENOUS